The susceptibility of 31 Candida auris clinical isolates was evaluated by four methods, namely the microdilution reference method according to Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines as well as Etest and VITEK 2. Essential agreement between the two reference methods was 90percent-flag-change. Etest showed a better overall agreement with the reference methods (94percent-flag-change and 81percent-flag-change for CLSI and EUCAST, respectively) than VITEK 2 (70percent-flag-change and 72percent-flag-change, respectively). Discrepancies were found for fluconazole (FLC) and amphotericin B. Considering categorical agreement (CDC tentative breakpoints), the majority of isolates were considered FLC-resistant (93.6percent-flag-change and 80.6percent-flag-change by CLSI and EUCAST, respectively). Furthermore, all isolates were considered susceptible to echinocandins by all methods. Susceptibility results should be interpreted with care if the VITEK 2 system is used to guide therapeutic decisions for C. auris infections.
